The immune cells that are the major targets of immune checkpoint inhibitors (stem-like PD-1+ CD8 T cells) are present in HPV+ tumors from head and neck cancer patients, according to a new study. The results have implications for how immunotherapy could be used to treat this type of head and neck cancer.